1. Home
  2. Stocks
  3. ASX
  4. CYP

Logo of Cynata Therapeutics (ASX:CYP)Latest Cynata Therapeutics (ASX:CYP) News

Page 3
Page 3 of 3
Cynata’s iPSC-Derived MSCs Outperform Conventional Cells in Key Regenerative Functions

Cynata’s iPSC-Derived MSCs Outperform Conventional Cells in Key Regenerative Functions

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.
Ada Torres
5 Feb 2025
Cynata Advances with Positive Diabetic Foot Ulcer Trial and $10.5m Cash Buffer

Cynata Advances with Positive Diabetic Foot Ulcer Trial and $10.5m Cash Buffer

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.
Ada Torres
30 Jan 2025